In the BioHarmony Drug Report Database
Spinraza (nusinersen) is an oligonucleotide pharmaceutical. Nusinersen was first approved as Spinraza on 2016-12-23. It is used to treat spinal muscular atrophy in the USA. It has been approved in Europe to treat spinal muscular atrophy. Spinraza’s patents are valid until 2035-09-11 (FDA).
Image (chem structure or protein)